Avoro Capital Advisors LLC - Q3 2023 holdings

$6.41 Billion is the total value of Avoro Capital Advisors LLC's 46 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .

 Value Shares↓ Weighting
ASND BuyASCENDIS PHARMAsponsored adr$343,658,800
+7.5%
3,670,000
+2.5%
5.36%
+23.6%
KRYS BuyKRYSTAL BIOTECH INC$297,604,380
-1.0%
2,565,555
+0.2%
4.64%
+13.8%
MRTX BuyMIRATI THERAPEUTICS INC$290,399,971
+44.7%
6,666,666
+20.0%
4.53%
+66.4%
MDGL BuyMADRIGAL PHARMACEUTICALS INC$227,092,200
-35.1%
1,555,000
+2.6%
3.54%
-25.4%
BuyMOONLAKE IMMUNOTHERAPEUTICSclass a ord$113,999,943
+29.6%
1,999,999
+15.9%
1.78%
+49.0%
RARE BuyULTRAGENYX PHARMACEUTICAL INC$53,475,000
+54.6%
1,500,000
+100.0%
0.83%
+77.8%
NewSTRUCTURE THERAPEUTICS INCsponsored adr$50,420,0001,000,000
+100.0%
0.79%
AKRO NewAKERO THERAPEUTICS ORD$28,099,972555,555
+100.0%
0.44%
RCKT NewROCKET PHARMACEUTICALS INC$25,612,5001,250,000
+100.0%
0.40%
BuyTANGO THERAPEUTICS INC$25,022,220
+359.6%
2,222,222
+35.5%
0.39%
+427.0%
CERE NewCEREVEL THERAPEUTICS HLDNG$20,859,766955,555
+100.0%
0.32%
ARWR BuyARROWHEAD PHARMACEUTICALS INC$15,181,550
+19.1%
565,000
+58.1%
0.24%
+37.0%
TSHA NewTAYSHA GENE THERAPIES INC$12,403,0003,925,000
+100.0%
0.19%
MRUS NewMERUS N V$10,479,990444,444
+100.0%
0.16%
QQQ NewInvesco QQQ Trustput$1,220,000500,000
+100.0%
0.02%
NewAEGLEA BIOTHERAPEUTICS INC$140,36111,458
+100.0%
0.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

Compare quarters

Export Avoro Capital Advisors LLC's holdings